指南与共识头颈部肿瘤放疗放疗物理与技术

头颈癌放射敏感性检测指导治疗干预的医生接受度:德尔菲共识研究

Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer: A Delphi consensus study.
指南 / 共识 · Clin Transl Radiat Oncol · 2026-06-01

本研究通过德尔菲共识调查评估头颈癌专家对放射敏感性检测和NTCP建模用于指导治疗及支持性决策的接受度。专家共识认为现有放射敏感性生物标志物和NTCP建模成熟度不足以在临床试验外改变主要治疗决策,支持性干预措施普遍可接受,而生物标志物指导的治疗调整仍属研究性。

要点

  • 放射敏感性检测和NTCP建模尚不支持临床试验外的主要治疗决策改变。
  • 支持性干预措施在常规头颈癌实践中被广泛接受。
  • 放射敏感性检测指导的治疗调整仍属研究性,应在临床试验中评估。

核心结论

  • 专家认为放射敏感性检测和NTCP建模有前景但尚未准备好用于常规治疗决策。
  • 支持性干预在常规头颈癌实践中被广泛接受,而放射敏感性检测指导的治疗调整仍属研究性,目前应在临床试验中评估。

研究设计与样本

  • 在头颈癌专家中开展德尔菲共识调查,评估对放射敏感性检测临床适用性、验证要求及整合用于指导治疗干预的看法。

主要发现

  • 专家明确区分支持性干预与放射敏感性检测指导的治疗调整。
  • 专家同意当前放射敏感性生物标志物和NTCP建模成熟度不支持临床试验外的主要治疗决策改变。
  • 十条陈述达成共识,包括IMRT为标准、个体化营养随访和治疗后监测为常规实践;一条被拒绝。
  • 复杂病例中放射敏感性检测和高风险患者质子转诊获部分同意,预防性胃造瘘未达共识。
  • 支持性措施在常规实践中一致被认为可接受,而生物标志物指导的治疗调整主要在临床试验内获支持。

关键数值与推荐

  • 十条陈述达成共识,包括IMRT为标准、个体化营养随访和治疗后监测为常规实践。
  • 一条陈述被拒绝。
  • 复杂病例中放射敏感性检测和高风险患者质子转诊获部分同意。
  • 预防性胃造瘘未达共识。
  • 外部验证确认支持性护理条目高度一致,对基于试验的生物标志物指导策略支持中等。

临床怎么用

  • 支持性干预措施如个体化营养随访和治疗后监测可常规用于头颈癌实践。
  • 放射敏感性检测指导的治疗调整应在临床试验框架内进行。
  • IMRT应作为标准放疗技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiosensitivity biomarkers hold promise for personalized radiotherapy but their clinical maturity and acceptability remain uncertain in head and neck cancer (HNC). This study assessed expert consensus on the potential integration of radiosensitivity testing and Normal Tissue Complication Probability (NTCP) modeling to inform therapeutic and supportive decisions. MATERIAL AND METHODS: A Delphi consensus survey was conducted among HNC specialists to evaluate perceptions of clinical applicability, validation requirements, and integration of radiosensitivity testing to guide therapeutic interventions, including test-guided treatment modifications and combination with NTCP models. RESULTS: A clear distinction emerged between supportive-care interventions and radiosensitivity test-guided treatment adaptations. Experts agreed that the current level of maturity of radiosensitivity biomarkers and NTCP modeling does not support major changes to primary treatment decisions outside clinical trials. Ten statements reached consensus, including IMRT as standard, individualized nutritional follow-up, and post-treatment surveillance as routine practice; one reached rejection. Partial agreement was observed for radiosensitivity testing in complex cases and for proton referral in high-risk patients, while preventive gastrostomy showed no consensus. Supportive-care measures were consistently considered acceptable in routine practice, whereas biomarker-guided treatment adaptations were mainly supported within clinical trials. External validation confirmed high concordance for supportive-care items and moderate support for trial-based biomarker-guided strategies. CONCLUSIONS: Experts considered radiosensitivity testing and NTCP modeling as promising yet not ready for routine therapeutic decision-making. Supportive-care interventions are widely accepted in routine HNC practice, whereas radiosensitivity test-guided treatment adaptations remain investigational and should currently be evaluated within clinical trials.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Thariat J, Beddok A, Salas S, et al. Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer: A Delphi consensus study. Clin Transl Radiat Oncol. 2026. PMID: 42305414. doi:10.1016/j.ctro.2026.101208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。